Vanguard Group’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-80,612
| Closed | -$253K | – | 4380 |
|
|
2020
Q4 | $253K | Buy |
80,612
+11,583
| +17% | +$38.1K | ﹤0.01% | 4064 |
|
|
2020
Q3 | $213K | Buy |
69,029
+34,665
| +101% | +$157K | ﹤0.01% | 3951 |
|
|
2020
Q2 | $160K | Sell |
34,364
-84,614
| -71% | -$439K | ﹤0.01% | 3946 |
|
|
2020
Q1 | $616K | Sell |
118,978
-785
| -0.7% | -$5.68K | ﹤0.01% | 3625 |
|
|
2019
Q4 | $599K | Hold |
119,763
| – | – | ﹤0.01% | 3761 |
|
|
2019
Q3 | $946K | Buy |
119,763
+3,294
| +3% | +$25.7K | ﹤0.01% | 3667 |
|
|
2019
Q2 | $844K | Buy |
116,469
+70
| +0.1% | +$512 | ﹤0.01% | 3722 |
|
|
2019
Q1 | $931K | Buy |
116,399
+26,743
| +30% | +$251K | ﹤0.01% | 3640 |
|
|
2018
Q4 | $717K | Buy |
89,656
+3,605
| +4% | +$43.2K | ﹤0.01% | 3655 |
|
|
2018
Q3 | $1.32M | Sell |
86,051
-546
| -0.6% | -$6.58K | ﹤0.01% | 3650 |
|
|
2018
Q2 | $771K | Buy |
86,597
+11,269
| +15% | +$99.9K | ﹤0.01% | 3752 |
|
|
2018
Q1 | $665K | Buy |
75,328
+7,239
| +11% | +$74.4K | ﹤0.01% | 3732 |
|
|
2017
Q4 | $695K | Buy |
68,089
+54,636
| +406% | +$660K | ﹤0.01% | 3684 |
|
|
2017
Q3 | $208K | Buy |
13,453
+6,871
| +104% | +$81.1K | ﹤0.01% | 3912 |
|
|
2017
Q2 | $59K | Buy |
6,582
+1,924
| +41% | +$37.7K | ﹤0.01% | 4019 |
|
|
2017
Q1 | $122K | Buy |
4,658
+3,355
| +257% | +$120K | ﹤0.01% | 3972 |
|
|
2016
Q4 | $58K | Sell |
1,303
-1,197
| -48% | -$38.2K | ﹤0.01% | 4017 |
|
|
2016
Q3 | $39K | Sell |
2,500
-100
| -4% | -$2.76K | ﹤0.01% | 4049 |
|
|
2016
Q2 | $86K | Hold |
2,600
| – | – | ﹤0.01% | 4039 |
|
|
2016
Q1 | $65K | Sell |
2,600
-633
| -20% | -$16.9K | ﹤0.01% | 4060 |
|
|
2015
Q4 | $161K | Buy |
3,233
+106
| +3% | +$11.8K | ﹤0.01% | 4037 |
|
|
2015
Q3 | $559K | Buy |
3,127
+35
| +1% | +$6.89K | ﹤0.01% | 3818 |
|
|
2015
Q2 | $443K | Buy |
3,092
+33
| +1% | +$4.58K | ﹤0.01% | 3898 |
|
|
2015
Q1 | $413K | Hold |
3,059
| – | – | ﹤0.01% | 3877 |
|
|
2014
Q4 | $548K | Sell |
3,059
-84
| -3% | -$14.9K | ﹤0.01% | 3697 |
|
|
2014
Q3 | $755K | Sell |
3,143
-14
| -0.4% | -$4.68K | ﹤0.01% | 3590 |
|
|
2014
Q2 | $1.38M | Hold |
3,157
| – | – | ﹤0.01% | 3394 |
|
|
2014
Q1 | $1.45M | Buy |
3,157
+98
| +3% | +$50.9K | ﹤0.01% | 3342 |
|
|
2013
Q4 | $1.47M | Sell |
3,059
-80
| -3% | -$39.1K | ﹤0.01% | 3310 |
|
|
2013
Q3 | $1.51M | Hold |
3,139
| – | – | ﹤0.01% | 3247 |
|
|
2013
Q2 | $1.48M | Buy |
+3,139
| New | +$1.42M | ﹤0.01% | 3176 |
|
Other funds holding IDXG
Vanguard Group's IDXG Position: Q1 2021 in Review
Vanguard Group sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2021, closing a stake of 80,612 shares — an estimated $253K sold.
Vanguard Group first reported a position in IDXG in Q2 2013 and held it in 31 quarters. The position peaked at $1.51M in Q3 2013. 3 funds tracked by Wall St. Rank hold IDXG as of Q1 2021.
- Vanguard Group reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
- Vanguard Group sold 80,612 Interpace Biosciences, Inc. Common Stock shares in Q1 2021, an estimated $253K.
- Vanguard Group first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 31 quarters.
- Vanguard Group's Interpace Biosciences, Inc. Common Stock position peaked at $1.51M in Q3 2013.
- 3 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2021.
Based on Vanguard Group's 13F filing for Q1 2021, filed 14 May 2021.